South African women less likely to receive dolutegravir during early rollout

During the early rollout of dolutegravir in South Africa, women were less likely to receive the new treatment than men, despite dolutegravir being associated with improved outcomes, researchers found.
“Dolutegravir has been recommended by the WHO for first-line ART since 2018 and has now been extensively rolled out in low- and middle-income countries,” Jienchi Dorward, BSc, MBChB, MRCGP, MSc, an academic researcher at the Centre for the AIDS Programme of Research in South Africa, told Healio, adding that early in the rollout, however, there were concerns about the potential risk of

During the early rollout of dolutegravir in South Africa, women were less likely to receive the new treatment than men, despite dolutegravir being associated with improved outcomes, researchers found.
“Dolutegravir has been recommended by the WHO for first-line ART since 2018 and has now been extensively rolled out in low- and middle-income countries,” Jienchi Dorward, BSc, MBChB, MRCGP, MSc, an academic researcher at the Centre for the AIDS Programme of Research in South Africa, told Healio, adding that early in the rollout, however, there were concerns about the potential risk of